CHICAGO, April 3, 2020 /PRNewswire/ — Aon plc (NYSE: AON) today unveiled an interactive web application that forecasts the impact of COVID-19 on employee populations throughout the U.S.
Aon, a leading global professional services firm providing a broad range of risk, retirement and health solutions, designed the tool to help employers anticipate medical costs, absenteeism and potential needs to shift work operations due to the spread of COVID-19.
“COVID-19 has brought on uncertainties in many aspects of our lives and this application will help employers understand their risks,” said Tim Nimmer, global chief actuary of Health Solutions for Aon. “Aon’s COVID-19 Employee Impact Model forecasts the impact on your employee population based on geographic-specific infection rates and advanced epidemiologic models.”
Aon’s COVID-19 Employee Impact Model works by using de-identified demographic data on employee populations and dependents covered by the employer’s health plan. Aon’s application combines employer-specific data with geographic infection rates from the most reputable epidemiologic models. * It is updated daily based on the spread of the virus, social distancing measures taken by local governments, and the current figures of confirmed patients, hospitalizations, deaths, and testing and treatment patterns.
The tool allows employers to estimate the impact of the virus through the fall on their employee population. By selecting a date, employers can see projected cases and medical claims cost, which can change daily based on the most current COVID-19 information.
“Aon consultants will work with employers to build plans on how to keep employees safe while minimizing disruptions to their operations,” Nimmer added. “In these uncertain times, it is important that organizations have the most current information from which to base their decisions to safely maintain vital operations.”
Key features allow employers to:
Members of Aon’s Actuarial & Analytics Practice, who developed the cloud-based platform, are working to also quantify productivity and the broader business impact by adding metrics that model workers’ compensation claims, time lost, salary replacement costs, disability and life insurance, and cost savings of deferred elective medical procedures.
The application initially will be available in the U.S. and is recommended for employers with at least 300 employees. It will be expanded globally soon.
For more information about the COVID-19 Employee Impact Model, contact your Aon representative or visit https://www.aon.com/forms/2020/coronavirus-contact-us-form.jsp.
* Epidemiologic model sources reviewed for Aon’s COVID-19 Employee Health Model include The COVID Tracking Project, the Centers of Disease Control and Prevention, the Kaiser Family Foundation, Harvard University, The Lancet, The Journal of the American Medical Association, The New England Journal of Medicine and Imperial College London.
About Aon
Aon plc (NYSE:AON) Aon is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.
Follow Aon on Twitter: https://twitter.com/Aon_plc
Visit the Aon Newsroom: http://www.aon.com/home/newsroom/index.html
Media Contact:
Robert Elfinger, robert.elfinger@aon.com, 312-381-0071
View original content to download multimedia:http://www.prnewswire.com/news-releases/aon-forecasts-workforce-impact-of-covid-19-with-interactive-web-application-301034298.html
SOURCE Aon plc
- Revenue increase of over 600%Dallas, Georgia--(Newsfile Corp. - July 2, 2024) - Bemax Inc.…
VANCOUVER, BC / ACCESSWIRE / July 2, 2024 / 1933 Industries Inc. (the "Company" or…
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a…
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a…
The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid…
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG…